Is GRN Holding Corporation (GRNF) a Buy, Sell, or Hold?
OTC : GRNF
GRN Holding Corporation — News
$0.039 USD
$0.0 (-2.26%)
- Volume
- 43.87K
- Average Volume
- 164.44K
- Market Capitalization
- $1.37M
- P/E Ratio
- -16.96
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.20
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.00
| Source | Headline |
|---|---|
|
Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data
Denali Therapeutics (DNLI) maintains a "Strong Buy" rating following FDA Accelerated Approval of AVLAYAH for Hunter Syndrome and robust pipeline momentum. Company's DNL593 for FTD-GRN is differentiated by restoring both extracellular and lysosomal PGRN; phase 1/2 data readout expected by end of 2026. AVLAYAH's full approval depends on confirmatory COMPASS study results; commercial performance remains unproven post-April 2026 launch. seekingalpha.com - 2026-05-27 07:54:16 |
